Crispr Therapeutics shares tumble after significant earnings miss
Resideo Technologies Inc (NYSE:REZI) stock reached a notable milestone by hitting a 52-week high of 28.32 USD, with the company now commanding a market capitalization of $4.13 billion. According to InvestingPro analysis, the stock is trading slightly above its Fair Value, with a P/E ratio of 90x. This achievement underscores a period of growth for the company, reflecting a positive market sentiment over the past year. Over the last 12 months, Resideo Technologies has experienced a significant increase in its stock value, with a 1-year change of 22.84%. The company’s robust performance is evidenced by its 14% revenue growth and strong liquidity position, with a current ratio of 1.94. InvestingPro subscribers have access to 8 additional key insights and a comprehensive Pro Research Report, offering deeper analysis of REZI’s financial health and growth prospects.
In other recent news, Resideo Technologies reported impressive financial results for the first quarter of 2025, surpassing analysts’ expectations. The company achieved an adjusted earnings per share of $0.63, significantly higher than the projected $0.28. Revenue for the quarter reached $1.77 billion, slightly above the anticipated $1.75 billion. Additionally, Resideo Technologies announced the appointment of Jeffrey Kutz as Senior Vice President and Chief Accounting Officer, effective immediately. Mr. Kutz, a Certified Public Accountant, previously served as Vice President and Chief Accounting Officer at Quaker Chemical (NYSE:KWR) Corporation. He succeeds Michael Carlet, who had been serving as the company’s principal accounting officer. These developments reflect ongoing changes and growth within Resideo Technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.